Janssen Korea is solidifying its lead in the ₩50 billion pulmonary arterial hypertension market in Korea.

Whether the company will be able to maintain the share it has built up so far after terminating the co-promotion agreement with Handok remains a large variable.

◆The market for the rare disease pulmonary arterial hypertension expands to record ₩50 billion

According to the pharmaceutical market research institution IQVIA, the market size for pulmonary arterial hypertension treatments last year was estimated at ₩51.4 billion.

This market is steadily expanding with the discovery of new patients. Sales in the market in Q1 this year reco